IRVINE, Calif., April 11, 2019 /PRNewswire/ -- Cryoport,
Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the
life sciences industry, today announced it has been selected by Celularity, a world leading allogeneic cell therapy company, to
utilize its complete range of temperature-controlled solutions.
Cryoport is the life sciences industry's foremost temperature-controlled logistics provider, supporting over 357 clinical
trials globally as well as blockbuster FDA-approved CAR-T therapies from Novartis and Gilead.
Celularity is a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from human
placentas through its proprietary IMPACT™ platform across immuno-oncology, inflammatory & age-related diseases. The agreement
will give Celularity access to Cryoport's full suite of temperature-controlled logistics solutions, including the Cryoport
Express® shippers, the industry-leading Cryoportal® Logistics Management Platform, Smartpak II™ Condition Monitoring System and
24/7/365 logistics support.
Jerrell Shelton, Chief Executive Officer of Cryoport, said, "We are proud to support
Celularity's clinical programs for the development of transformative allogeneic cell therapies. Cryoport's end-to-end,
industry-leading, temperature-controlled logistics solutions protect the biologic commodities that underpin these potentially
ground-breaking therapies and play a vital role in their development."
John R. Haines, Chief Administrative Officer of Celularity, said, "Celularity's IMPACT™
platform seamlessly integrates biosourcing through advanced cell manufacturing and productization of allogeneic placental-derived
cell therapeutics. Industry-leading supply chain management tools are critical to our ability to deliver transformative,
on-demand, off-the-shelf therapeutic options to patients in the United States and worldwide. We
look forward to partnering with Cryoport for cell therapy product logistics management."
About Celularity, Inc.
Celularity, headquartered in Warren, New Jersey, is a clinical-stage cell therapeutics
company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta. Using proprietary
technology in combination with its IMPACTTM platform, Celularity is the only company to harness the versatility of
placenta-derived cells ashighly scalable, off-the-shelf treatments for patients with cancer, inflammatory and age-related
diseases. To learn more, please visit www.celularity.com.
About Cryoport, Inc.
Cryoport is a trusted global provider of temperature-controlled logistics solutions for life sciences commodities
during distribution, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as
regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care,
CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive
medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and
reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal® Logistics Management Platform,
leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics
expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.
Cryoport is dedicated to: simplifying global cold chain logistics through innovative technology, unmatched monitoring and data
capture and support, including consulting; delivering the most advanced temperature-controlled logistics solutions for the life
sciences industry; and providing vital information that provides peace of mind throughout the life of each logistics process.
For more information, visit www.cryoport.com. Sign up to follow @cryoport on Twitter at www.twitter.com/cryoport.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s
intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's
actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical
development risks. The Company's business could be affected by a number of other factors, including the risk factors listed from
time to time in the Company's SEC reports including, but not limited to, the Company's 10-K for the year ended December 31, 2018 filed with the SEC. The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press release.
View original content to download multimedia:http://www.prnewswire.com/news-releases/celularity-selects-cryoports-temperature-controlled-logistics-solutions-300830412.html
SOURCE Cryoport, Inc.